Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a Study of ABBV-142 in Healthy Adults
NCT06774313Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of ABBV-142 (9 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events, Maximum Observed Serum Concentration of ABBV-142 and 7 more. Started Jan 2025; status: completed.
02
Drugs
ABBV-142
Beyond the preview
Go deeper on NCT06774313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06774313.